There are currently 143 ongoing clinical trials involving Low Back Pain
Of the 143 trials,61 trials are in Phase II
Furthermore, 37 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Low Back Pain, a Central Nervous System disorder. Asia-Pacific, North America and Europe are some of the prominent regions engaged in Low Back Pain-related drug trials.
Low Back Pain related clinical trial sponsors
University of Utah, Massachusetts General Hospital, Asahi Kasei Pharma Corp, and Laboratorios Silanes SA de CV are some of the notable clinical trial sponsors involved in Low Back Pain. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Low Back Pain
Aspirin (Cardio Aspirin/ Adiro), Celecoxib (Celebrex/ Onsenal/ Celebra/ Artilog/ Celecox), and Duloxetine hydrochloride (Cymbalta / Xeristar /Ariclaim/Nodetrip/ Andepra) are among the key marketed drugs involving Low Back Pain.
Duloxetine hydrochloride (Cymbalta / Xeristar /Ariclaim/Nodetrip/ Andepra) is a naphthalene derivative act as anti-depressive agent. It functions via Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2) Inhibitor; Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4) Inhibitor mechanism of action. It is formulated as enteric coated hard gelatin capsules for oral route of administration. Duloxetine is marketed for the treatment of Low Back Pain and several other indications including Depression, Osteoarthritis Pain, Major Depressive Disorder, Generalized Anxiety Disorder (GAD), Fibromyalgia (Fibromyalgia Syndrome), Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathy, Myalgia (Muscle Pain), Peripheral Neuropathic Pain. Duloxetine hydrochloride was first approved in 2004 and is marketed globally including the US, the UK, China, Japan, and Germany by several pharma giants including Eli Lilly and Co, and Esteve Pharmaceuticals SA.
Aspirin (Cardio Aspirin/ Adiro) is a phenol esters derivative acts as antiplatelet agent. It functions via Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1) Inhibitor; Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1) Inhibitor mechanism of action. It is formulated as gastro-resistant or delayed release tablets for oral route of administration. Aspirin is marketed for the treatment of Low Back Pain and several other indications including Cardiovascular Disease, Angina (Angina Pectoris), Cardiovascular Risk Factors, Thrombosis, Myocardial Infarction, Venous Thromboembolism, Migraine, Neuropathic Pain (Neuralgia), Dysmenorrhea, Stroke, Cerebral Infarction (Brain Infarction), Nasopharyngitis (Common Cold), Unstable Angina, Ischemic Stroke, Pulmonary Embolism, Ischemia. Aspirin was first approved in 1965 and is marketed globally including the US, the UK, China, Japan, and Germany by Bayer AG and its subsidiaries.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward